Anbrutinib

安鲁替尼

Report date: 2022/01/18 17:04:09
NME

Base Information

Drug NameAnbrutinib
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase BTK inhibitors
TargetsTyrosine-protein kinase BTK
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesAnrun Medicine Technology (Suzhou) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAnrun Medicine Technology (Suzhou) Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A